Anthem Biosciences Holds 20th Annual General Meeting, Approves FY2025-26 Financials and Key Director Appointments
Anthem Biosciences Limited held its 20th Annual General Meeting (AGM) on Wednesday, July 22, 2026. The meeting was conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), with the company reviewing its operational and financial performance for the fiscal year ended March 31, 2026.The AGM saw the Chairperson address members regarding the company's reflections on FY 2025-26, highlighting key strategic initiatives, the successful listing of the Company, business outlook, and long-term growth plans. Chief Financial Officer Mohammed Gawir Baig provided shareholders with a comprehensive overview of the operational and financial performance for FY 2025-26, outlining the company’s achievements in both areas.
Prior to the meeting, members were informed that the Reports of the Statutory Auditors for the financial year ended March 31, 2026 did not contain any qualification, reservation, or adverse remark and were taken as read by the members.
The AGM agenda included several ordinary and special business matters. The resolutions passed by the members focused on the adoption of annual results, director appointments, and corporate transactions.
A summary of the key resolutions transacted during the 20th AGM is provided below:
| Type | Resolution Description | Status |
|---|---|---|
| Ordinary Business | Approval for adoption of the audited financial statements (including consolidated financial statements) for the financial year ended March 31, 2026 and the reports of the Board of Directors and Auditors. | Passed |
| Ordinary Business | Approval for Declaration of dividend. | Passed |
| Ordinary Business | Appointment of M/S. S.R. Batliboi & Associates LLP, chartered accountants, as the statutory auditors of the Company. | Passed |
| Ordinary Business | Re-appointment of Mr. K Ravindra Chandrappa who retires by rotation and offered himself for re-appointment. | Passed |
| Special Resolution | Approval of the continuation of Mr. Ravikant Uppal as non-executive independent director upon attaining the age of 75 years. | Passed |
| Ordinary Business | Approval of commission payable to Independent Directors. | Passed |
| Ordinary Business | Approval for increase in payment of remuneration to related parties holding an office or place of profit. | Passed |
| Ordinary Business | Approval of the Upside Sharing Arrangement with Viridity Tone LLP. | Passed |
The meeting provided an opportunity for members who registered as speakers to express their views and seek clarifications from the management, which were appropriately addressed by the Chairperson. The voting process concluded after a 15-minute extension, allowing all members to exercise their rights. The Scrutinizer confirmed that all resolutions set out in the notice convening the AGM were passed by the Members with the requisite majority.
ANTHEM Stock Price Movement
Shares of Anthem Biosciences Limited slipped on Wednesday, closing at ₹778.9 after shedding 1.71% from the previous close. The stock settled amid significant activity, trading a total volume of 4.42 million shares throughout the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.